Novartis shareholders approve the proposed 100% Spin-off of Sandoz

At an Extraordinary General Meeting, Novartis shareholders approved the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of Novartis.

Shareholders also approved an ordinary capital decrease of the share capital of Novartis AG in the amount of the share capital of Sandoz.

from Breaking World Pharma News https://ift.tt/kQFIltE